Drug Trial Radar · NCT01359982
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Sep 2011
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.
Conditions
- Malignant Solid Tumor
- Lymphomas
Interventions
RRx-001Drug
Dose level 1 (10 mg/m2)
RRx-001Drug
Dose Level 2 (16.7 mg/m2)
RRx-001Drug
Dose Level 3 (24.6 mg/m2)
RRx-001Drug
Dose Level 4 (33 mg/m2)
RRx-001Drug
Dose Level 5 (55.0 mg/m2)
RRx-001Drug
Dose Level 6 (83 mg/m2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Who Had an Adverse EventsTime frame: From time of receiving a dose of RRx-001 through 92 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Moores University of California San Diego Cancer Center
La Jolla, California
Sarah Cannon Research Institute
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.